Table 1.
Study number | Author | Study design | Mean age | Sex (% female) | Mean BMI | Biopsy-proven NAFLD in total (n) | Biopsy-proven NAFLD in exercise group (n) |
---|---|---|---|---|---|---|---|
1 | Hickman et al. [16] | RCT | 48 | 38 | 34 | 21 | 9 |
2 | Eckard et al. [17] | RCT | 50 | 39 | 35 | 56 | 9 |
3 | Naimimohasses et al. [18] | NRCT | 58 | 60 | 35 | 50 | 16 |
4 | O’Gorman et al. [19] | NRCT* | 60 | 71 | 36 | 24 | 16 |
5 | Rezende et al. [22] | RCT | 55 | 100 | 33 | 40 | 19 |
6 | Stine et al. [23] | RCT | 50 | 61 | 35 | 28 | 18 |
7 | Houghton et al. [24] | RCT | 54 | n.r. | 33 | 24 | 12 |
8 | Kistler et al. [20] | Cross-sectional | 48 | 63 | n.r. | 813 | n.a. |
9 | Lahelma et al. [21] | Cross-sectional | 51 | 65 | 40 | 100 | n.a. |
BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; RCT, randomized controlled trial; NRCT, non-randomized controlled trial; n.r., not reported; n.a., not applicable.
Non-randomized controlled trial design for non-invasive test endpoints; uncontrolled trial design for histological endpoints.